Videos

At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...

At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.

During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory...

At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...

At the 65th ASH Annual Meeting, Swetha Kambhampati, MD, shares data on the real-world outcomes of brexucabtagene autoleucel treatment for patients with R/R mantle cell lymphoma, including high-risk subgroups.

At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...

Gurdeep S. Mannu, DPhil, FRCS, gave a comprehensive overview of axillary treatment for patients with early breast cancer.

Amy Tiersten, MD, Mount Sinai, discussed results from the phase 1/2 ASPIRE study investigating combination anastrozole, palbociclib, trastuzumab, and pertuzumab for previously untreated patients with HR-positive, HER2-positive metastatic...

At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...

At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.